Cystic fibrosis: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CFTR 29
• GLP-1 2
• G6PD 0
• IL-13 0
• MUC1 0
• NF1 1
• PDE4 0
• STAT3 0
• CTNNB1 0
• DMD 1
• EGFR 0
• ERK 0
• HDAC 0
• HMGB1 0
• HTT 1
• IL-1 0
• IL-17 0
• IL-4 0
• IL-6 0
• mTOR 0
• NLRP3 0
• NRF2 0
• PKD1 0
• PPAR 0
• SGLT2 0
• SMN1 1
• TLR4 0

24 of 71+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Discovery and evolution of CRISPR-Associated Transposons (CAST) for functional RNA-guided integration (CRAFT)

  Kobenhavns Universitet· Kobenhavn, Denmark· EU contribution €263,393· until Aug 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  A doctoral training programme for next-generation LUNG-targeted non-viral GENEtic MEDicines (LUNG-GENEMED)

  Politecnico di Milano· Milano, Italy· EU contribution €3,876,613· until Nov 2030· 7 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Maternal human milk as a Risk factor to the Early-life Exposome (MATREEX)

  King's College London· London, United Kingdom· EU contribution €345,235· until Feb 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  In vitro and in situ structural characterization of the biofilm-associated functional amyloids in Pseudomonas aeruginosa bacteria (FAPbulous)

  Deutsches Elektronen-Synchrotron Desy· Hamburg, Germany· EU contribution €202,125· until Dec 2027

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  CellCourier: programmable drug delivery via combinatorial cell targeting and generative design of tailored binding peptides

  Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit und Umwelt Gmbh· Neuherberg, Germany· EU contribution €150,000· until Jun 2027

  The disease is named only in the funder's project summary, not in the title.

5 of 11 running projects, newest first. Listed amounts together: €19.9m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Validation of Therapeutic Efficacy Targeting the Splicing Variants in Cystic Fibrosis and CFTR Pathologies

  NCT05100823· University Hospital, Montpellier· Updated 18 Sept 2025

  “Enrolment period completed and sufficient number of enrolments to achieve study objectives”Registry text, quoted unchanged. Source

• Terminated

  Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)

  NCT05392855· University of Missouri-Columbia· Updated 20 Sept 2024

  “Low recruitment, low interest from participant population”Registry text, quoted unchanged. Source

• Withdrawn

  A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis

  NCT05095246· Krystal Biotech, Inc.· Updated 14 Aug 2023

  “Pandemic, logistical, and recruitment challenges”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Assessment of CFTR-Modulator Treatment in Cystic Fibrosis Lung Disease Using Novel Structural and Functional MRI

  NCT04391322· The Hospital for Sick Children· Source

• TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age

  NCT07048574· State University of New York at Buffalo· Source

• Safety of Stopping Pancreatic Enzyme Replacement Therapy in Children With Improved Pancreatic Function After Highly Effective Modulator Therapy

  NCT07632768· Indiana University· Source

• Establishment of a Primary Epididymal Cell Model From Epididymal Samples to Study CFTR Gene Regulation

  NCT06045702· University Hospital, Brest· Source

• A study to test how well BI 3720931 is tolerated and whether it improves lung function in people with cystic fibrosis (LenticlairTM 1)

  2023-503281-23-00· Boehringer Ingelheim International GmbH· Source

• Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI

  NCT02848560· Children's Hospital Medical Center, Cincinnati· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 5
• Organoids 20
• CRISPR-Cas Systems 12
• Gene Expression Profiling 13
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 16
• Exome Sequencing 5
• Proteomics 12
• Metabolomics 9
• Mass Spectrometry 4
• Flow Cytometry 2
• Immunohistochemistry 3
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 21
• Machine Learning 6
• Deep Learning 3
• Cohort Studies 37
• Genome-Wide Association Study 3

• CFTR modulators exert subset-specific phenotype remodeling on circulating neutrophils in cystic fibrosis.

  Immunohorizons, Jul 2026

• SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans.

  Br J Clin Pharmacol, Aug 2011

See which targets of this disease your abstract mentions, and go to the people working on them.